Inspira Technologies Receives Key Priming Patent Supporting the INSPIRA ART500 Respiratory Support Device

Inspira Technologies has announced this issuance of a key U.S. patent for its INSPIRA ART500 respiratory support device. The INSPIRA ART500 is an advanced respiratory medical device that directly oxygenates blood for patients in need of respiratory support rather relying on mechanical ventilation systems which are linked to up to 50% mortality rates, heightened coma risks, bacterial infections, and mechanical ventilation-related lung injuries, the system uses a canula directly inserted into the jugular vein. Blood is then oxygenated by the platform and CO₂ is removed. In the United States, approximately 50,000 patients rely on ventilators each day. These mechanical ventilation systems are essential for individuals experiencing respiratory failure, severe pneumonia, and acute respiratory distress syndrome (ARDS). It’s noteworthy that nearly 40% of intensive care unit (ICU) patients necessitate mechanical ventilation support.

This newly granted patent centers around the automated self-priming module engineered for the INSPIRA ART500 device. The device features a proprietary self-automated priming module designed to ensure a secure and clot-free connection to the patient’s vascular system, thereby reducing the risks associated with clot formation and blood flow reduction. The patent comprises nine distinctive claims, all characterized by their novelty, inventive merit, and practical applicability. Beyond the United States, the Company has also initiated patent applications in Europe and various countries across different regions.

Dagi Ben-Noon, CEO of Inspira, expressed his optimism about the patent approval, viewing it as a testament to their unique solution’s value. He sees it as a major milestone in the development of the INSPIRATM ART500 system and a significant stride towards providing a global medical solution. The company is actively committed to converting their innovative ideas into tangible value for their stakeholders. This patent approval serves as a testament to their unwavering dedication to advancing respiratory care and transforming the landscape of medical solutions for the better.